CN104940844A - 一种治疗肝火上炎型心悸失眠的中药制剂及其制备方法 - Google Patents
一种治疗肝火上炎型心悸失眠的中药制剂及其制备方法 Download PDFInfo
- Publication number
- CN104940844A CN104940844A CN201510424373.6A CN201510424373A CN104940844A CN 104940844 A CN104940844 A CN 104940844A CN 201510424373 A CN201510424373 A CN 201510424373A CN 104940844 A CN104940844 A CN 104940844A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- liver
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 84
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 title claims abstract description 69
- 206010022437 insomnia Diseases 0.000 title claims abstract description 67
- 238000002360 preparation method Methods 0.000 title claims abstract description 51
- 206010033557 Palpitations Diseases 0.000 title claims abstract description 47
- 238000011282 treatment Methods 0.000 claims abstract description 34
- 239000002994 raw material Substances 0.000 claims abstract description 25
- 241000218176 Corydalis Species 0.000 claims abstract description 18
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 44
- 210000000582 semen Anatomy 0.000 claims description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 239000000843 powder Substances 0.000 claims description 26
- 241000628997 Flos Species 0.000 claims description 25
- 229940079593 drug Drugs 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 17
- 230000008901 benefit Effects 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 12
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 12
- 241000217407 Margaritifera Species 0.000 claims description 11
- 239000006187 pill Substances 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 8
- 238000007873 sieving Methods 0.000 claims description 8
- 239000007921 spray Substances 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 7
- 238000002481 ethanol extraction Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 238000005507 spraying Methods 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000013618 particulate matter Substances 0.000 claims description 4
- 230000006837 decompression Effects 0.000 claims description 2
- 238000010410 dusting Methods 0.000 claims description 2
- 239000003480 eluent Substances 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 238000004064 recycling Methods 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 abstract description 92
- 239000008280 blood Substances 0.000 abstract description 90
- 210000004369 blood Anatomy 0.000 abstract description 84
- 230000000694 effects Effects 0.000 abstract description 41
- 210000004556 brain Anatomy 0.000 abstract description 29
- 208000011580 syndromic disease Diseases 0.000 abstract description 16
- 230000001737 promoting effect Effects 0.000 abstract description 15
- 230000007958 sleep Effects 0.000 abstract description 13
- 230000017531 blood circulation Effects 0.000 abstract description 12
- 238000000034 method Methods 0.000 abstract description 9
- 230000006872 improvement Effects 0.000 abstract description 6
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 210000004204 blood vessel Anatomy 0.000 abstract description 4
- 230000001276 controlling effect Effects 0.000 abstract description 4
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract description 3
- 208000020016 psychiatric disease Diseases 0.000 abstract description 3
- 241001080798 Polygala tenuifolia Species 0.000 abstract description 2
- 240000001341 Reynoutria japonica Species 0.000 abstract 2
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 2
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- 240000007185 Albizia julibrissin Species 0.000 abstract 1
- 235000011468 Albizia julibrissin Nutrition 0.000 abstract 1
- 244000236521 Bupleurum rotundifolium Species 0.000 abstract 1
- 235000015221 Bupleurum rotundifolium Nutrition 0.000 abstract 1
- 241000050051 Chelone glabra Species 0.000 abstract 1
- 235000007516 Chrysanthemum Nutrition 0.000 abstract 1
- 235000014375 Curcuma Nutrition 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 244000111489 Gardenia augusta Species 0.000 abstract 1
- 235000018958 Gardenia augusta Nutrition 0.000 abstract 1
- 241000212322 Levisticum officinale Species 0.000 abstract 1
- 241000830535 Ligustrum lucidum Species 0.000 abstract 1
- 235000003805 Musa ABB Group Nutrition 0.000 abstract 1
- 240000008790 Musa x paradisiaca Species 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 235000015266 Plantago major Nutrition 0.000 abstract 1
- 244000179560 Prunella vulgaris Species 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 241000157373 Uncaria rhynchophylla Species 0.000 abstract 1
- 235000007212 Verbena X moechina Moldenke Nutrition 0.000 abstract 1
- 240000001519 Verbena officinalis Species 0.000 abstract 1
- 235000001594 Verbena polystachya Kunth Nutrition 0.000 abstract 1
- 235000007200 Verbena x perriana Moldenke Nutrition 0.000 abstract 1
- 235000002270 Verbena x stuprosa Moldenke Nutrition 0.000 abstract 1
- 240000008866 Ziziphus nummularia Species 0.000 abstract 1
- 239000002249 anxiolytic agent Substances 0.000 abstract 1
- 235000005272 common selfheal Nutrition 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 1
- 238000009499 grossing Methods 0.000 abstract 1
- 239000001645 levisticum officinale Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 40
- 206010003549 asthenia Diseases 0.000 description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 31
- 201000010099 disease Diseases 0.000 description 30
- 230000006870 function Effects 0.000 description 29
- 208000002193 Pain Diseases 0.000 description 28
- 208000007443 Neurasthenia Diseases 0.000 description 27
- 230000036407 pain Effects 0.000 description 27
- 208000002173 dizziness Diseases 0.000 description 21
- 230000007812 deficiency Effects 0.000 description 20
- 231100000614 poison Toxicity 0.000 description 20
- 210000003734 kidney Anatomy 0.000 description 18
- 206010019233 Headaches Diseases 0.000 description 15
- 231100000869 headache Toxicity 0.000 description 15
- 230000036541 health Effects 0.000 description 13
- 230000008961 swelling Effects 0.000 description 13
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 12
- 206010062717 Increased upper airway secretion Diseases 0.000 description 12
- 208000026435 phlegm Diseases 0.000 description 12
- 239000003440 toxic substance Substances 0.000 description 12
- 235000009508 confectionery Nutrition 0.000 description 11
- 210000005036 nerve Anatomy 0.000 description 11
- 230000036461 convulsion Effects 0.000 description 10
- 230000004438 eyesight Effects 0.000 description 10
- 206010010904 Convulsion Diseases 0.000 description 9
- 206010022998 Irritability Diseases 0.000 description 9
- 230000010354 integration Effects 0.000 description 9
- 230000003340 mental effect Effects 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 9
- 206010030113 Oedema Diseases 0.000 description 8
- 230000001914 calming effect Effects 0.000 description 8
- 230000004064 dysfunction Effects 0.000 description 8
- 206010016256 fatigue Diseases 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 239000002574 poison Substances 0.000 description 8
- 239000003053 toxin Substances 0.000 description 8
- 231100000765 toxin Toxicity 0.000 description 8
- 206010010726 Conjunctival oedema Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 206010027514 Metrorrhagia Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 208000004880 Polyuria Diseases 0.000 description 7
- 208000009205 Tinnitus Diseases 0.000 description 7
- 230000002567 autonomic effect Effects 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 7
- 230000035619 diuresis Effects 0.000 description 7
- 208000001848 dysentery Diseases 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 231100000886 tinnitus Toxicity 0.000 description 7
- 208000006820 Arthralgia Diseases 0.000 description 6
- 206010007247 Carbuncle Diseases 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 6
- 208000001780 epistaxis Diseases 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 241000411851 herbal medicine Species 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 201000004792 malaria Diseases 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000002269 spontaneous effect Effects 0.000 description 6
- 230000035900 sweating Effects 0.000 description 6
- 210000001835 viscera Anatomy 0.000 description 6
- 206010012335 Dependence Diseases 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 230000009429 distress Effects 0.000 description 5
- 208000006750 hematuria Diseases 0.000 description 5
- 230000023597 hemostasis Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 201000007227 lymph node tuberculosis Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 208000019116 sleep disease Diseases 0.000 description 5
- 208000020685 sleep-wake disease Diseases 0.000 description 5
- 230000002936 tranquilizing effect Effects 0.000 description 5
- 201000000736 Amenorrhea Diseases 0.000 description 4
- 206010001928 Amenorrhoea Diseases 0.000 description 4
- 206010050012 Bradyphrenia Diseases 0.000 description 4
- 208000015220 Febrile disease Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 208000019255 Menstrual disease Diseases 0.000 description 4
- 208000001140 Night Blindness Diseases 0.000 description 4
- 206010047513 Vision blurred Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 231100000540 amenorrhea Toxicity 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 210000000232 gallbladder Anatomy 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 208000037920 primary disease Diseases 0.000 description 4
- 230000021595 spermatogenesis Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 208000036119 Frailty Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000034507 Haematemesis Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 206010043458 Thirst Diseases 0.000 description 3
- 208000012886 Vertigo Diseases 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 230000035568 catharsis Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000003205 diastolic effect Effects 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 206010013990 dysuria Diseases 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000002996 emotional effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 239000002398 materia medica Substances 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 230000000474 nursing effect Effects 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000003860 sleep quality Effects 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- 231100000033 toxigenic Toxicity 0.000 description 3
- 230000001551 toxigenic effect Effects 0.000 description 3
- 231100000889 vertigo Toxicity 0.000 description 3
- 230000009978 visual deterioration Effects 0.000 description 3
- 230000002618 waking effect Effects 0.000 description 3
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010029333 Neurosis Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- 208000005946 Xerostomia Diseases 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 230000001166 anti-perspirative effect Effects 0.000 description 2
- 239000003213 antiperspirant Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- VRSRXLJTYQVOHC-YEJXKQKISA-N corydaline Chemical compound C=1([C@H]2[C@H]3C)C=C(OC)C(OC)=CC=1CCN2CC1=C3C=CC(OC)=C1OC VRSRXLJTYQVOHC-YEJXKQKISA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 230000005059 dormancy Effects 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 208000024756 faint Diseases 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 208000015238 neurotic disease Diseases 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 208000024335 physical disease Diseases 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000004206 stomach function Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 201000002327 urinary tract obstruction Diseases 0.000 description 2
- 229940096998 ursolic acid Drugs 0.000 description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- NPUIQANQRDIHLU-UHFFFAOYSA-N 3-(4-chlorophenyl)sulfonylbutanoic acid Chemical compound OC(=O)CC(C)S(=O)(=O)C1=CC=C(Cl)C=C1 NPUIQANQRDIHLU-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- NULBHTHMVOCGOE-ZBCCAYPVSA-N 7-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-3-[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@H](OC=2C=C3C(C(C=C(O3)C=3C=CC(O)=CC=3)=O)=C(O)C=2)O1 NULBHTHMVOCGOE-ZBCCAYPVSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 235000005637 Brassica campestris Nutrition 0.000 description 1
- 241001301148 Brassica rapa subsp. oleifera Species 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000131317 Capitulum Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 206010009346 Clonus Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- VRSRXLJTYQVOHC-UHFFFAOYSA-N Corydaline Natural products CC1C2C=3C=C(OC)C(OC)=CC=3CCN2CC2=C1C=CC(OC)=C2OC VRSRXLJTYQVOHC-UHFFFAOYSA-N 0.000 description 1
- 241000830532 Corydalis yanhusuo Species 0.000 description 1
- QRMPRVXWPCLVNI-UHFFFAOYSA-N Curcumenol Natural products C1C(=C)C2CCC(C)C22CC(C(C)C)C1(O)O2 QRMPRVXWPCLVNI-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 240000001008 Dimocarpus longan Species 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 235000000235 Euphoria longan Nutrition 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 206010049708 Feeling guilty Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 201000001916 Hypochondriasis Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000004356 Hysteria Diseases 0.000 description 1
- IQSFEAHJUMVILC-UHFFFAOYSA-N Isorhynchophyllic acid Natural products CCC1CN2CCC3(C2CC1C(=COC)C(=O)O)C(=O)Nc4ccccc34 IQSFEAHJUMVILC-UHFFFAOYSA-N 0.000 description 1
- DAXYUDFNWXHGBE-VKCGGMIFSA-N Isorhynchophylline Chemical compound O=C1NC2=CC=CC=C2[C@]11CCN2C[C@H](CC)[C@@H](\C(=C/OC)C(=O)OC)C[C@H]21 DAXYUDFNWXHGBE-VKCGGMIFSA-N 0.000 description 1
- VCNYNWHVJKWJRQ-UHFFFAOYSA-N Isorhynchophylline Natural products CCC1=CN2CCC3(C2CC1C(=COC)C(=O)OC)C(=O)Nc4ccccc34 VCNYNWHVJKWJRQ-UHFFFAOYSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 235000006439 Lemna minor Nutrition 0.000 description 1
- 244000242291 Lemna paucicostata Species 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010050819 Musculoskeletal chest pain Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010029897 Obsessive thoughts Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 241000218180 Papaveraceae Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000208966 Polygala Species 0.000 description 1
- 241000208977 Polygalaceae Species 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- GTRPODKMSBFDOI-UHFFFAOYSA-N Protopine Natural products CN1Cc2c3OCOc3ccc2C4C1Cc5cc6OCOc6cc5C4=O GTRPODKMSBFDOI-UHFFFAOYSA-N 0.000 description 1
- ZAALQOFZFANFTF-UHFFFAOYSA-N Pseudoprotipine Natural products C1=C2C(=O)CC3=CC=4OCOC=4C=C3CN(C)CCC2=CC2=C1OCO2 ZAALQOFZFANFTF-UHFFFAOYSA-N 0.000 description 1
- 208000012545 Psychophysiologic disease Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- DAXYUDFNWXHGBE-KAXDATADSA-N Rhynchophylline Chemical compound O=C1NC2=CC=CC=C2[C@@]11CCN2C[C@H](CC)[C@@H](\C(=C/OC)C(=O)OC)C[C@H]21 DAXYUDFNWXHGBE-KAXDATADSA-N 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 1
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 231100000132 chronic toxicity testing Toxicity 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- ISFMXVMWEWLJGJ-NZBPQXDJSA-N curcumenol Chemical compound CC1=C[C@](O2)(O)C(=C(C)C)C[C@@]22[C@@H](C)CC[C@H]21 ISFMXVMWEWLJGJ-NZBPQXDJSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- CHWPMFMUQATVNK-ARYYTZDLSA-N dihydrosporogen AO-1 Natural products O[C@H]1[C@]2(C(C)=C)O[C@@H]2[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1 CHWPMFMUQATVNK-ARYYTZDLSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000013364 duck meat Nutrition 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Natural products CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 201000003995 melancholia Diseases 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- STKUCSFEBXPTAY-KCWGXYKVSA-N nuezhenoside Natural products COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C(=CC)[C@@H]1CC(=O)OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O STKUCSFEBXPTAY-KCWGXYKVSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000009323 psychological health Effects 0.000 description 1
- 230000008433 psychological processes and functions Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229960001473 sulfobromophthalein sodium Drugs 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 239000002918 waste heat Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种治疗肝火上炎型心悸失眠的中药制剂,所述中药制剂包括以下重量份数的原料:夜交藤10~20份,钩藤10~20份,远志10~20份,茯神10~20份,柏子仁10~20份,酸枣仁10~20份,柴胡10~20份,川芎10~20份,延胡索10~20份,栀子10~20份,马鞭草10~20份,制首乌10~20份,女贞子10~20份,五味子10~20份,合欢皮10~20份,珍珠母10~20份,莪术10~20份,白芍10~20份,车前子10~20份,黄芩10~20份,菊花10~20份,生地10~20份,夏枯草10~20份。根据血瘀论及肝主血,调血的理论,采用活血化瘀、疏肝调血(即调理脑血管壁舒缩功能)而达治疗目的。神经衰弱症见上述证候者,能较好的达到改善睡眠的功效。
Description
技术领域
本发明涉及含有来源于植物组份的保健品,特别涉及一种治疗肝火上炎型心悸失眠的中药制剂及其制备方法。
背景技术
心悸包括惊悸和怔忡,均为中医病名。是指病人自觉心中悸动,惊恐不安,甚则不能自主的一种症状。失眠是指经常不能获得正常的睡眠而言。不寐的情况有多种,或不易入睡,或寐而易醒,醒后不能再度入睡,甚至彻夜不眠。总之,心悸和愉眠往往并见,也常与头晕、头痛、耳鸣、健忘等症相互夹杂,每因情绪波动或劳累过度而发作。多见于西医学中的各种心心脏病,神经功能症、神经衰弱、植物神经功能紊乱等症。
心悸失眠的病因很多,自责心理:有些人因为一次过失后,感到内疚自责,在脑子里重演过失事件,并懊悔自己当初没有妥善处理。白天由于事情多,自责懊悔情绪稍轻,到夜晚则“徘徊”在自责、懊悔的幻想与兴奋中,久久难眠。
期待心理:担心睡过头误事,因而常出现早醒。比如一位“三班倒”的网站管理员,由于上大夜班(夜里12时上班),常于晚7时睡觉。他因害怕迟到睡得不踏实,常常睡上1~2个小时就被惊醒,久之便成了早醒患者。也有的人在晋升、职称评定、分房结果快要公布前,处于期待兴奋状态,难以入睡。
童年创伤心理的再现:有的人由于童年时受到丧失父母、恐吓、重罚等创伤而感到害怕,出现了怕黑夜不能入睡的现象。但成年期后,由于受到某种类似儿童时期的创伤性刺激,就会使被压抑在潜意识的童年创伤性心理反应再现,重演童年时期的失眠现象。
现在脑力劳动者越来越多,许多人开始出现睡眠质量不好、神经衰弱、用脑过度症状,如记忆力下降、思维迟钝,失眠健忘等。但是,还是有很多人对于怎样才是用脑过度不太了解,对于用脑过度的危害也缺乏认识。专家指出,长期用脑过度不注意调整的话,可能诱发神经衰弱、失眠等疾病。因此,应该努力避免用脑过度的发生。专家强调,长期用脑过度导致的生理和心理机能失衡,可能诱发神经衰弱、失眠症等一系列严重的精神障碍性疾病。因此,对于用脑过度千万不要掉以轻心,应及时加以防范。
肝火上炎型症状见心悸而烦、急躁易怒、失眠梦、脉弦细数。此类患者可选用具有清肝泻火、养心安神作用的食物进行食补,如:菠菜、油菜、荠菜、冬瓜、苦瓜、竹笋、鲜藕、芹菜、雍菜、黄花菜、小麦、桑椹、梨、桃、葵花子、绿豆、桂圆、鸡蛋、羊肉、鸭肉、乌骨鸡、蜂蜜等。肝开窍于目,目的视觉功能主要依赖肝之阴血的濡养;肝的经脉又上联目系。因此,肝的功能正常与否常常在目上反映出来。例如:肝血不足可出现视物模糊、夜盲;肝阴亏损,则两目干涩、视力减退;肝火上炎,则目赤肿痛。中医强调,人要经常疏肝气、清肝毒、降肝火、养肝血,疏肝气可使全身气机疏泄通畅,体内不堵则面上无痘;清肝毒可化解消除体内污染,体内无毒则脸无暗色;降肝火可使体内阴阳平衡,体内不焦则皮肤滋润不燥;养肝血可以滋养全身脏器,肝血充盈则体表光泽有弹性。修复受损肝脏,使全身气机疏泄条达,全身气血顺畅运行,以达到疏肝养颜目的。产生毒素的源头是肝。当肝不能很好地完成解毒工作时,毒素就在体内漫延。疏肝养颜首先从肝脏健康入手,让健康的肝脏完成各项解毒工作,彻底切断毒素来源,让容颜持久美丽。
现在市面上出售的各种保健品、药品鱼龙混杂,大多数只是虚假宣传的噱头,有的不仅没有保健成分,还造成人身体的巨大伤害。可是中药气味清苦,很多人不愿长期服用;即使服用,是药三分毒,让人长期服用时也产生抗拒心理。用脑过度会引起植物神经功能失调,从而引起脑血管舒缩功能异常,供血不足,出现头晕头痛胸闷、失眠健忘等症状。根据血瘀论及肝主血,调血的理论,采用活血化瘀、疏肝调血(即调理脑血管壁舒缩功能)而达治疗目的。本发明精选中药材,都是能长久使用而不伤害人体,且能明显提高记忆力,恢复大脑营养、改善睡眠的良材。
发明内容
本发明所要解决的技术问题在于,城市生活压力越来越大,现代人脑力劳动者越来越多,许多人开始出现用脑过度症状,如记忆力下降、思维迟钝等。更多的是惊悸和怔忡。现在市场上出现各种补脑益智,安神的保健品,药品很多都有副作用,产生依赖性,伤害人体。本发明具有补肾益精、化痰开窃、补脑益智、活血化癖作用。本发明清肝败火,滋阴补肾、生精补髓,益气养血,强脑安神。用于肝火上炎、气血两亏所致的头晕、乏力、健忘、心悸失眠;神经衰弱症见上述证候者,能较好的达到改善睡眠的功效。
为解决上述技术难题,本发明提供一种治疗肝火上炎型心悸失眠的中药制剂,其所述中药制剂包括以下重量份数的原料:夜交藤10~20份,钩藤10~20份,远志10~20份,茯神10~20份,柏子仁10~20份,酸枣仁10~20份,柴胡10~20份,川芎10~20份,延胡索10~20份,栀子10~20份,马鞭草10~20份,制首乌10~20份,女贞子10~20份,五味子10~20份,合欢皮10~20份,珍珠母10~20份,莪术10~20份,白芍10~20份,车前子10~20份,黄芩10~20份,菊花10~20份,生地10~20份,夏枯草10~20份。
所述治疗肝火上炎型心悸失眠的中药制剂,其所述中药制剂中各种原料的重量份数可以为:夜交藤10~15份,钩藤10~15份,远志10~15份,茯神10~15份,柏子仁10~15份,酸枣仁10~15份,柴胡10~15份,川芎10~15份,延胡索10~15份,栀子10~15份,马鞭草10~15份,制首乌10~15份,女贞子10~20份,五味子10~20份,合欢皮10~20份,珍珠母10~20份,莪术10~20份,白芍10~20份,车前子10~20份,黄芩10~20份,菊花10~20份,生地10~20份,夏枯草10~20份。
所述所述治疗肝火上炎型心悸失眠的中药制剂,其所述中药制剂中各种原料的重量份数还可以为:夜交藤10~20份,钩藤10~20份,远志10~20份,茯神10~20份,柏子仁10~20份,酸枣仁10~20份,柴胡10~20份,川芎10~20份,延胡索10~20份,栀子10~20份,马鞭草10~20份,制首乌10~20份,女贞子10~15份,五味子10~15份,合欢皮10~15份,珍珠母10~15份,莪术10~15份,白芍10~15份,车前子10~15份,黄芩10~15份,菊花10~15份,生地10~15份,夏枯草10~15份。
为解决上述技术问题,本发明还提供一种治疗肝火上炎型心悸失眠的中药制剂的制备方法,其所述中药制剂为丸剂时的制备步骤为:
a、取所有原料放入乙醇浸泡,热提取2次,为组分1;
b、将上述提取的药渣加水提取2次,为组分2;
c、将组分1与组分2合并浓缩;干燥成粉末罐装胶囊。
所述步骤a中,可以取所有原料药泡入乙醇中,浸泡2小时以上,分别加占原料药总质量的8倍量、6倍量的乙醇提取2次,提取时间为2小时、1小时;合并2次提取液,提取液通过管式离心,得离心液,离心液过D 101大孔树脂进行吸附,先用水洗除杂,然后用70%的乙醇进行洗脱,收集洗脱液,减压浓缩,成浸膏,为组分成1。
所述步骤b中,可以将提取过的药渣加水,浸泡1-2小时;将浸泡好的药渣置多功能提取罐中煎煮二次;第一次加占其质量10倍量的水,煎煮1.5~2小时,取煎液,滤过;第二次加占其7倍量的水,煎煮1~1.2小时,取两次煎液混合,滤过;将上述两种提取液合并,浓缩成浸膏,作为组分2。
所述步骤c中,可以将上述步骤得到的组分1与组分2混合,置入双效真空浓缩器中,浓缩成膏状,回收乙醇,然后通入喷雾干燥机进行喷雾干燥,过喷雾干燥机喷头的压缩空气压力为4kg/m2,干燥室热气流温度是80℃,得原料药粉;罐装胶囊。
为解决上述技术问题,本发明再提供一种治疗肝火上炎型心悸失眠的中药制剂的制备方法,所述中药制剂为丸剂时的制备步骤为:
a.将所述原料放入粉碎机粉碎后过筛;
b.将过筛后剩下的颗粒物放入乙醇中加热回流提取2次;
c.再取上述乙醇提取后的药渣,加水加热回流提取1次;
d.将上述两种提取液合并,减压回收乙醇并喷雾干燥,得药粉;混合过筛得到的细粉加蜂蜜搓成丸剂。
所述步骤a中,可以将所述原料放入粉碎机粉碎后过120目细筛,使能通过120目筛的细粉量在达到30%,收集通过120目筛的原料细粉备用;所述步骤b中,将过筛后剩下的颗粒物放入乙醇中加热回流提取2次,每次1~2小时,将2次提取液合并静置。
所述步骤c中,可以将上述乙醇提取过的药渣加10倍量水加热1~2小时回流提取1次;将上述3次提取液合并静置;所述步骤d中,将上述提取液合并,减压浓缩相对密度为80℃时1.28的滤液,回收乙醇,将所得滤液调整比重到1.50,通入喷雾干燥机进行喷雾干燥,过喷雾干燥机喷头的压缩空气压力为4kg/m2,干燥室热气流温度是80℃,得原料药粉;将过筛后得到的原料细粉与乙醇提炼药粉混合,加蜂蜜搓成丸剂。
本发明有益的技术效果在于,针对现代人脑力劳动者越来越多,城市生活压力巨大,许多人开始出现用脑过度、心悸失眠的症状,如记忆力下降、神经衰弱、思维迟钝等,心悸失眠。用脑过度会引起植物神经功能失调,从而引起脑血管舒缩功能异常,供血不足,出现头晕头痛胸闷、睡眠质量不高等症状。本发明具有清肝败火,滋阴补肾、生精补髓,益气养血,强脑安神。补肾益精、化痰开窃、补脑益智、活血化癖作用,用于肝火上炎、气血两亏所致的头晕、乏力、健忘、心悸失眠;神经衰弱症见上述证候者,能较好的达到改善睡眠的功效。并且纯中药制剂,不会产生依赖性。对人身体无损害。本发明口感好,微苦甘醇;再加上一些补脑益智、恢复大脑营养、改善睡眠并且口感清淡,使人易于接受,能较好的达到改善神经衰弱的功效。
具体实施方式
心悸包括惊悸和怔忡,均为中医病名。是指病人自觉心中悸动,惊恐不安,甚则不能自主的一种症状。失眠是指经常不能获得正常的睡眠而言。不寐的情况有多种,或不易入睡,或寐而易醒,醒后不能再度入睡,甚至彻夜不眠。总之,心悸和失眠往往并见,也常与头晕、头痛、耳鸣、健忘等症相互夹杂,每因情绪波动或劳累过度而发作。多见于西医学中的各种心心脏病,神经功能症、神经衰弱、植物神经功能紊乱等症。
经常失眠会影响我们的正常工作和生活。经常失眠的朋友们由于白天没有精神往往导致白天精神不振,工作效率低,紧张易怒,与周围人相处不融洽,抑郁、烦闷、严重的还会导致悲观厌世。记忆力减退、头痛。失眠后往往会导致白天精神不振,头昏脑胀,耳鸣。导致健忘,神经衰弱等。经常失眠可引起大脑功能失调,分析、处理问题能力减退。
神经衰弱是指大脑由于长期的情绪紧张和精神压力,从而产生精神活动能力的减弱,其主要特征是精神易兴奋和脑力易疲劳,睡眠障碍,记忆力减退,头痛等,伴有各种躯体不适等症状,病程迁延,症状时轻时重,病情波动常与社会心理因素有关。大多数病例发病于16-40岁之间,两性发病数无明显差异。从事脑力劳动者占多数。本病如处理不当可迁延达数年甚或数十年。如遇新的精神因素或休息不足,症状可重现或加剧。但经精神科或心理科医生积极、及时治疗,指导病人消除病因,正确对待疾病,本病可达缓解或治愈,预后一般良好。
肝开窍于目,目的视觉功能主要依赖肝之阴血的濡养;肝的经脉又上联目系。因此,肝的功能正常与否常常在目上反映出来。例如:肝血不足可出现视物模糊、夜盲;肝阴亏损,则两目干涩、视力减退;肝火上炎,则目赤肿痛。中医强调,人要经常疏肝气、清肝毒、降肝火、养肝血,疏肝气可使全身气机疏泄通畅,体内不堵则面上无痘;清肝毒可化解消除体内污染,体内无毒则脸无暗色;降肝火可使体内阴阳平衡,体内不焦则皮肤滋润不燥;养肝血可以滋养全身脏器,肝血充盈则体表光泽有弹性。修复受损肝脏,使全身气机疏泄条达,全身气血顺畅运行,以达到疏肝养颜目的。产生毒素的源头是肝。当肝不能很好地完成解毒工作时,毒素就在体内漫延。疏肝养颜首先从肝脏健康入手,让健康的肝脏完成各项解毒工作,彻底切断毒素来源,让容颜持久美丽。
中医认为肝主目:“肝气通于目,肝和则目能辨五色矣”。肝的病变往往影响及眼睛,这个心灵的窗户。现代都市上班族普遍使用电脑办公,再加上烟酒无度,夜生活不节制,熬夜,这些都直接伤害了肝气。如肝血不足,则两目干涩,视物不清或夜盲;肝经风热,可见目赤痒痛;肝火上炎,可见目赤生翳;肝阳上亢,则头目眩晕;肝风内动,可见目斜上视等。
根据血瘀论及肝主血,调血的理论,采用活血化瘀、疏肝调血(即调理脑血管壁舒缩功能)而达治疗目的。本发明精选中药材,都是能长久使用而不伤害人体,且能明显提高记忆力,恢复大脑营养、改善睡眠的良材。
白芍性凉,味苦酸,微寒,具有补血柔肝、平肝止痛。敛阴收汗等功效,适用于阴虚发热、月经不调、胸腹胁肋疼痛、四肢挛急,泻痢腹痛、自汗盗汗、崩漏、带下等症。芍药甙有抗菌、解热、抗炎、增加冠状动脉流量、改善心肌营养血流、扩张血管、对抗急性心肌缺血、抑制血小板聚集、镇静、镇痛、解痉、抗溃疡、调节血糖的作用。白芍煎剂能抑制痢疾杆菌、肺炎链球菌、大肠杆菌、伤寒杆菌、溶血性链球菌、绿脓杆菌等。血虚阴虚、胸腹胁肋疼痛、肝区痛、胆囊炎、胆结石疼痛、泻痢腹痛、妇女行经腹痛、自汗易汗盗汗、腓肠肌痉挛、四肢拘挛疼痛、不安腿综合症等病症患者适宜食用。
川芎入肝、脾、三焦三经。功用主治行气开郁,法风燥湿,活血止痛。治风冷头痛旋晕,胁痛腹疼,寒痹筋挛,经闭,难产,产后瘀阻块痛,痈疽疮疡。用于月经不调,经闭痛经,瘕腹痛,胸胁刺痛,跌扑肿痛,头痛,风湿痹痛。《纲目》载:″燥湿,止泻痢,行气开郁。″川芎嗪解除血管平滑肌(主动脉条)痉挛(肾上腺素、氯化钾引起)。还能扩张冠状血管,增加冠脉血流量。对抗垂体后叶素引起的心肌缺血缺氧。减轻结扎冠脉引起的心肌梗死病变程度。
钩藤味甘、性微寒。归肝,心包经。具有清热平肝、息风定惊功效。主治头痛眩晕、惊痫抽搐、妊娠子痫、高血压等。钩藤含有多种吲哚类生物碱,其中降压成分为异钩藤碱和钩藤碱。自发性高血压大鼠(SHR)连续每天灌胃给予钩藤煎剂10g/kg,第5周始见显著降压作用。钩藤的降压作用温和而缓慢,降压机制是抑制血管运动中枢、扩张外周血管,降低外周阻力,并能阻滞交感神经和神经节,抑制神经末梢递质的释放。钩藤碱松弛动脉作用还与钙拮抗有关。
女贞子,味甘苦、性凉,归肝肾经,具有滋补肝肾、益阴养血之功。现代医学研究证明,女贞子内含熊果酸、甘露醇、葡萄糖、脂肪油等,有强心、利尿和保肝作用,能使因化疗引起的白细胞下降数量升高,并对金黄色葡萄球菌、大肠杆菌有抑制作用。女贞子中含有齐墩果酸女贞子酸、女贞苷、熊果酸、硬脂酸、油酸、甘露醇、白桦脂醇、磷脂以及糖类如女贞子多糖、阿拉伯糖、葡萄糖等,还含有15种氨基酸,11种微量元素及挥发油等。研究认为女贞子有降血糖及降血脂并有抗动脉粥样硬化作用,还有抗菌、抗病毒作用,女贞子煎剂对金黄色葡萄球菌、福氏痢疾杆菌、伤寒杆菌、绿脓杆菌和大肠杆菌均有抑制作用。
远志(学名:Polygala tenuifolia Willd.)为远志科、远志属。产东北、华北、西北和华中以及四川。性温,味苦、辛,具有安神益智、祛痰、消肿的功能,用于心肾不交引起的失眠多梦、健忘惊悸,神志恍惚,咳痰不爽,疮疡肿毒,乳房肿痛。临床应用生远志、制远志和蜜远志三种。
酸枣仁中国最早的一部药书《神农本草经》中记载:“补中益肝,坚筋骨,助阴气,皆酸枣仁之功也。”明代李时珍《本草纲目》中记载,枣仁“熟用疗胆虚不得眠,烦渴虚汗之症;生用疗胆热好眠,皆足厥阴少阳药也。养肝,宁心,安神,敛汗。治虚烦不眠,惊悸怔忡,烦渴,虚汗。①《本经》:主心腹寒热,邪结气聚,四肢酸疼,湿痹。②《别录》:主烦心不得眠,脐上下痛,血转久泄,虚汗烦渴,补中,益肝气,坚筋骨,助阴气,令人肥健。③《药性论》:主筋骨风,炒末作汤服之。④《本草拾遗》:睡多生使,不得睡炒熟。⑤王好古:治胆虚不眠,寒也,炒服;治胆实多睡,热也,生用。⑥《本草汇言》:敛气安神,荣筋养髓,和胃运脾。⑦《本草再新》:平肝理气,润肺养阴,温中利湿,敛气止汗,益志定呵,聪耳明目。
延胡索(Corydalis yanhusuo W.T.Wang ex Z.Y.Su et C.Y.Wu),罂粟科、紫堇属多年生草本,别名:延胡、玄胡索、元胡索、元胡。中国传统药材。主要产于浙江和江苏。其块茎(夏天无)含紫堇碱、原阿片碱等多种生物碱,经制成粉剂或醋制流浸膏等,主治心腹腰膝诸痛;月经不调;症瘕;崩中;产后血晕;恶露不尽;跌打损伤。有镇痛、镇静、催眠作用。
中药何首乌有生首乌与制首乌之分,直接切片入药为生首乌,用黑豆煮汁拌蒸后晒干入药为制首乌。二者的功用有所不同:生首乌功能解毒、消痈、润肠通便,常用于治疗瘰疬疮痈、风疹瘙痒、肠燥便秘;制首乌功能补肝肾、益精血、乌须发、强筋骨,用于血虚萎黄、眩晕耳鸣、须发早白、腰膝酸软、肢体麻木、崩漏带下、久疟体虚等。本发明所采用的制首乌是补肾益肾的佳品。
合欢皮性味甘、平。有解郁、和血、宁心、消痈肿之功。有治心神不安、忧郁、失眠、肺痈、痈肿、瘰疠、筋骨折伤之效。《本草求真》:“合欢皮。合欢因何命名,其服之脏腑安养,令人欢欣怡悦,故以欢名。《本经》:主安五脏,和心志,令人欢乐无忧。常用于情志不遂忧郁而致失眠者、心神不宁等下,临床多与柏子仁、心参、酸枣仁等同用,以增强养心开郁、安神定志作用。
五味子温;酸、甘;归肺、心、肾经;收敛固涩,益气生津,补肾宁心。用于久嗽虚喘,梦遗滑精,遗尿尿频,久泻不止,自汗,盗汗,津伤口渴,短气脉虚,内热消渴,心悸失眠。《本草经疏》载:五味子主益气者,肺主诸气,酸能收,正入肺补肺,故益气也。其主咳逆上气者,气虚则上壅而不归元,酸以收之,摄气归元,则咳逆上气自除矣。劳伤赢瘦,补不足,强阴,益男子精。《别录》养五脏,除热,生阴中肌者,五味子专补肾,兼补五脏,肾藏精,精盛则阴强,收摄则真气归元,而丹田暖,腐熟水谷,蒸糟粕而化精微,则精自生,精生则阴长,故主如上诸疾也。
茯神味甘、淡、性平,入药具有利水渗湿、益脾和胃、宁心安神之功用。性味甘、淡平。有渗湿、健脾、宁心等功能。用于痰饮、水肿、小便不利、泄泻、心悸、眩晕。茯苓皮,利水消肿,用于水湿浮肿等症,用于心虚惊悸,健忘,失眠,惊痫,小便不利。《别录》:疗风眩,风虚,五劳,口干。止惊悸,多恚怒,善忘。开心益智,养精神。
珍珠母平肝潜阳;安神定惊;清肝明目考证。功用主治平肝,潜阳,定惊,止血。治头眩,耳鸣,心悸,失眠,癫狂,惊痫,吐血,衄血,妇女血崩。《中国医学大辞典》:滋肝阴,清肝火。治癫狂惊痫,头眩,耳鸣,心跳,胸腹膜胀,妇女血热,血崩,小儿惊搐发痉。《饮片新参》:平肝潜阳,安神魂,定惊痫,消热痞、眼翳。《吉林中草药》:止血。治吐血,衄血,崩漏。
夜交藤是何首乌的藤茎,因夜里会自动相互交合而得名,药用何首乌则是这种植物的块根。中医认为,夜交藤性平无毒,味甘微苦,入心、肝经,有安神养血、祛风通络的功效,主治阴虚血少、虚烦不眠、风湿痹痛、皮肤痒疹等症。夜交藤的煎服剂量一般为10~30克,还可煎水外洗或捣敷外用。主要的临床应用简介如下。失眠夜交藤具有养血安神作用,用于阴虚血少所致的失眠,常与合欢皮、酸枣仁、柏子仁、远志等药配合应用。
马鞭草,拉丁名Herba Verbenae Officinalis,苦,凉。归肝、脾经。清热解毒药;活血通经药;利水消肿药;截疟药;活血散瘀,截疟,解毒,利水消肿。用于症瘕积聚,经闭痛经,疟疾,喉痹,痈肿,水肿,热淋。《本草经疏》:马鞭草,本是凉血破血之药。下部阴疮者,血热之极,兼之湿热,故血污浊而成疮,且有虫也。血凉热解,污浊者破而行之,靡不瘥矣。陈藏器谓其破血杀虫,亦此意耳。《本草拾遗》:主症癖血癖,久疟,破血。作煎如糖,酒服。《日华子本草》:通月经,治妇人血气肚胀,月候不匀。《本草衍义补遗》:治金疮,行血,活血。
柴胡清虚热中药,用于感冒发热、寒热往来、疟疾、肝郁气滞、胸肋胀痛、脱肛、子宫脱落、月经不调。柴胡始载于《神农本草经》,列为上品。性微寒、味苦、辛、归肝经、胆经,具疏肝利胆、疏气解郁、散火之功效。功能:透表泄热,疏肝解郁,升举阳气。
车前子有利水通淋、清热解毒、清肝明目、祛痰、止泻的功效。归肝、肾、肺、小肠经。清热利尿,凉血,解毒。主治热结膀胱,小便不利,淋浊带下,暑湿泻痢,衄血,尿血,肝热目赤,咽喉肿痛,痈肿疮毒。车前草性味甘寒,具有利水、清热、明目、祛痰的功效。主治淋病、尿血、小便不通、黄疽、水肿、热痢、泄泻、目赤肿痛、喉痛等等。《草性论》载“治尿血,能补五脏,明目,利小晒干的车前草便,通五淋”。《本草逢原》载“若虚滑精气不固者禁用”。性味和功用甘,寒,归手太阳,阳明经。利水,清热,明目,祛痰,用于小便不通,淋浊,带下,尿血,黄疸,水肿,热痢泄泻,鼻衄,目赤肿痛,喉痛,咳嗽,皮肤溃疡。
黄芩(Scutellaria baicalensis Georgi),别名山茶根、土金茶根,是唇形科黄芩属的一种植物,属于半野生半家种品种,多年生草本植物。黄芩的根是一种草药,味苦、性寒,能清热燥湿、泻火解毒、止血、安胎。主治温热病、上呼吸道感染、肺热咳嗽、湿热黄胆、肺炎、痢疾、咳血、目赤、胎动不安、高血压、痈肿疖疮等症。黄芩的临床应用抗菌比黄连还好,而且不产生抗药性。
菊花是菊科植物菊花Chrysanthemum morifolium Ramat的干燥头状花序,是中国常用中药,具有疏风、清热、明目、解毒之功效。主要治疗头痛、眩晕、目赤、心胸烦热、疔疮、肿毒等症。现代药理研究表明,菊花具有治疗冠心病、降低血压、预防高血脂、抗菌、抗病毒、抗炎、抗衰老等多种药理活性。中国药用菊花在市场上有八大主流商品来源,分别为杭菊、亳菊、贡菊、滁菊、祁菊、怀菊、济菊、黄菊,而《中国药典》I部(2000年版)根据菊花产地和加工方法的不同,收载了亳菊、滁菊、贡菊和杭菊四个品种。
生地就是生地黄,具有清热凉血功效用于温热病热入营血,壮热神昏,口干舌绛。如清营汤。治温病后期,余热未尽,阴液已伤,夜热早凉,舌红脉数者,如青蒿鳖甲汤。可用于治温热病热入营血,血热毒盛,吐血衄血,斑疹紫黑。如四生丸;《神农本草经》:味甘,寒。主治折跌,绝筋,伤中,逐血痹,填骨髓,长肌肉。作汤除寒热积聚,除痹。生者尤良。《名医别录》:大寒。主治妇人崩中血不止,及产后血上薄心、闷绝,伤身、胎动、下血,胎不落,堕坠,宛折,瘀血,留血,衄血,吐血,皆捣饮之。《药性论》:君。能补虚损,温中下气,通血脉。治产后腹痛,主吐血不止。又云生地黄,味甘,平,无毒。解诸热,破血,通利月水闭绝。不利水道,捣薄心腹,能消瘀血。病人虚而多热,加而用之。
夏枯草夏枯草性寒,味甘、辛、微苦,具有清泄肝火、散结消肿、清热解毒、祛痰止咳、凉血止血的功效,适用于淋巴结核、甲状腺肿、乳痈、头目眩晕、口眼歪斜、筋骨疼痛、肺结核、血崩、带下、急性传染性黄疸型肝炎及细菌性痢疾等。现代药理研究表明,夏枯草有降低血压的作用,并能扩张血管,其所含芦丁有抗炎作用,并能降低血管通透性,减少脆性,降低肝脂。夏枯草还有抵制癌细胞的作用。《本经》:主寒热、瘰疬、鼠瘘、头疮,破症,散瘿结气,脚肿湿痹。《本草衍义补遗》:补养血脉。《滇南本草》:祛肝风,行经络,治口眼歪斜。行肝气,开肝郁,止筋骨疼痛、目珠痛,散瘰窃、周身结核。
莪术辛、苦,温。归肝、脾经。主治“气血凝滞,心腹胀痛,症瘕,积聚,宿食不消,妇女血瘀经闭,跌打损伤作痛。”有行气解郁,破瘀,止痛的功用。莪术醇提取物及挥发油对四氯化碳(CCI4)硫代乙酰胺(TAA)引起的小鼠丙氨酸转氨酶(ALT)升高有明显的降低作用,使磺溴酞钠(BSP)潴留量减少,相应肝组织病变减轻。
栀子是传统中药,属卫生部颁布的第1批药食两用资源,具有护肝、利胆、降压、镇静、止血、消肿等作用,在中医临床常用于治疗黄疸型肝炎、扭挫伤、高血压、糖尿病等症。主治热病心烦;肝火目赤;头痛;湿热黄疸;淋证;血痢尿血;口舌生疮;疮疡肿毒;扭伤肿痛。本品对目赤肿痛有很大疗效。该品清泻三焦热邪,可治肝胆火热上攻之目赤肿痛,常配大黄用,如栀子汤《圣济总录》。
具体实施例1:本发明口服液剂的制备
取原料夜交藤1500g,钩藤1500g,远志1500g,茯神1500g,柏子仁1500g,酸枣仁1500g,柴胡1500g,川芎1500g,延胡索1500g,栀子1500g,马鞭草1500g,制首乌1500g,女贞子1500g,五味子1500g,合欢皮1500g,珍珠母1500g,莪术1500g,白芍1500g,车前子1500g,黄芩1500g,菊花1500g,生地1500g,夏枯草1500g,加入5-10倍量的乙醇中浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩至膏状,静置备用,作为组分1;再将提炼过的药渣加水提取两次,每次30-45分钟,合并,成组分2;将组分1与组分2合并,置入双效真空浓缩器中,浓缩至90℃时相对密度为1.50的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含0.2g生药量,然后加糊精调和,紫外线灭菌,装瓶。
具体实施例2:本发明胶囊剂的制备
取原料夜交藤1200g,钩藤1300g,远志1200g,茯神1200g,柏子仁1200g,酸枣仁1200g,柴胡1100g,川芎1200g,延胡索1200g,栀子1200g,马鞭草1200g,制首乌1200g,女贞子1300g,五味子1200g,合欢皮1200g,珍珠母1200g,莪术1200g,白芍1200g,车前子1200g,黄芩1200g,菊花1200g,生地1200g,夏枯草1200g,取原料药洗净晾干,于70℃烘箱中,烘1-3h,取出置于干燥箱内冷却,用粉碎机粉碎过80-100目筛。将过筛的细粉备用,未过筛的粗颗粒一起泡入乙醇中1-2天后,加热提取2次,每次1-2小时,去上清液,合并提取液,100-110目滤过,再经截流分子量为6000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩至膏状,置入双效真空浓缩器中,浓缩至90℃时相对密度为1.50的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含0.2g生药量,然后干燥成粉剂,加过筛的细粉,紫外线灭菌,罐装胶囊。
具体实施例3:本发明丸剂的制备
取原料夜交藤1200g,钩藤1300g,远志1200g,茯神1200g,柏子仁1200g,酸枣仁1200g,柴胡1100g,川芎1200g,延胡索1200g,栀子1200g,马鞭草1200g,制首乌1200g,女贞子1300g,五味子1200g,合欢皮1200g,珍珠母1200g,莪术1200g,白芍1200g,车前子1200g,黄芩1200g,菊花1200g,生地1200g,夏枯草1200g,将其混合一起放入放入耐酸碱浸渍锅,在室温下,与70度以上乙醇一起浸渍3~7天,然后加热回流提取2次,每次1~2小时,将2次提取液合并静置,过滤,分离后取滤液;用纱布过滤,残渣中加入50-60%乙醇,60℃-70℃继续浸提2h,每10min搅拌一次,纱布过滤,合并浸提液,浓缩成糊状成为组分2;将组分1和组分2合并后,置入双效真空浓缩器中,浓缩至80℃时相对密度为1.60的浸膏,干燥成粉剂,加蜂蜜调和搓成丸剂。
药理学毒性试验
实验例1:本发明急性毒性试验
一、试验材料:动物:昆明种小鼠,体重18-25g,雌雄各半,山东大学生物试验室育种。药物:本发明(所有原材料混合煎煮2次,合并过滤,取药液)含0.0365mg/ml。
二、方法:
1、LD50计算:采用改良寇氏法,将小鼠随机分成5组,每组10只,雌雄各半,将本发明加蒸馏水溶解,配成最大浓度,按小鼠最大允许容量给药,所给剂量按生药量依次为18,14.4,11.5,9.2,7.4(g.kg-1),在动物禁食(不禁水)18小时后,一日内分两次给药(间隔半小时),每次0.5ml,观察动物死亡情况。
2、最大耐受剂量测定(MTD值):取小鼠20只,雌雄各10只。将本发明加蒸馏水溶解,配成最高浓度,按动物的最大耐受量,以注射灌喂器能抽动为准。在动物禁食(不禁水)18小时后,一日内分两次给药(间隔半小时),每次0.5ml(每ml含生药0.36g),总药量为18g生药/kg.d,相当临床成人50Kg体重用量的300倍。给药后连续观察7天。
三、试验结果:
在LD50计算中当用最大允许浓度和最大允许容量给予小鼠时(18g/Kg.d),未见小鼠死亡,即未测出LD50,只可求最大耐受剂量,在7天观察期中,动物其食欲、活动、毛色、精神状态等皆正常,发育正常,未见有死亡。即选用相当于临床剂量的300倍药量,并无不良反应发生,表明急性毒性极小,MTD>18g/Kg.d。
实验例2:急性毒性及长期毒性的试验结果
急性毒性试验:通过小白鼠一次性灌胃给予本发明,最高浓度35%,最大灌胃容量0.4ml/10g,剂量14g/kg(每g药粉相当于10g生药),连续观察7天,未发现任何毒性反应,因浓度和剂量无法增加,故未能测出该药的LD 50。最大耐受量测定:以最高浓度,最大灌胃容量,小白鼠灌胃给药3次,间隔5小时,然后连续观察7天,无一例死亡。药粉剂量为>42g/kg.日(每g药粉相当于10g生药),按公斤体重计算相当于成人临床日用量的420倍。
长期毒性试验:为观察长期用药是否产生毒性反应,分别给予大鼠本发明饲服,按成人临床日用量的70倍和35倍(即7g/kg/日和3.5g/kg/日),连续给喂8周,未见大鼠的行为、进食、体重出现异常,与对照组比,血常规,肝肾功能,各种重要脏器均无异常改变,在所用药剂量范围内,未曾发现本发明的任何毒副反应。通过动物的急慢性毒性试验证实,本发明安全范围较大,是一种安全可靠的保健品。
药理学实验:
神经衰弱是指精神容易兴奋和脑力容易疲乏,并常伴有情绪烦恼和一些心理生理症状,包括植物神经功能紊乱和睡眠障碍。这此症状不能归因于已存在的躯体疾病、脑器质性病变和某种特定的精神疾病。神经衰弱是临床常见病种,而且在临床各科都可能碰到。尤其是近年随着社会变化节奏加快、工作生活压力增大,神经衰弱发病率有逐年上升的趋势。
本发明人于2010年10月-2012年2月,应用本发明治疗神经衰弱90例,取得了较为满意的疗效,现报告如下。
1 资料与方法
1.1 诊断标准
1.1.1 中医诊断标准:参照中国中西医结合研究会精神病专业委员会制订的神经症中西医结合辨证分型标准,结合《中药新药临床研究指导原则(第一辑)》关于失眠和《中药新药临床研究指导原则(第二辑)》关于本病的标准制订。本研究主要关注心悸失眠、神经衰弱症,所以本中医诊断标准综合了痰湿内停的证候和郁证、失眠的精神症状。作者拟定了神经衰弱痰湿内停证的以下几个主要证候:①头晕或头痛;②心悸;③胸闷;④体倦乏力;⑤失眠或多梦、易醒;⑥胃纳不佳;⑦口淡不渴;⑧舌淡红,舌苔白腻、白滑或白润,符合以上二项加第⑧项即可诊断为神经衰弱证。
1.1.2 西医诊断标准:神经衰弱的主要特点为:①与精神易兴奋相联系的精神易疲劳;②情绪症状(烦恼、易激惹和紧张感);③心理生理障碍,包括睡眠障碍、头部不适感以及个别内脏功能的轻度或中度障碍,包括消化系统和性功能障碍,或心血管系统和呼吸功能障碍。症状存在三个月以上,又没有任何其他精神障碍的症状,神经系统和身体检查无阳性发现。
症状学标准至少应具备以下五项中的三项:衰弱症状:如精神疲乏、脑力迟钝,注意力难以集中,记忆困难,工作或学习不能持久、效率降低。兴奋症状:工作或学习用脑均可引起精神兴奋;回忆及联想增多,控制不住;可对声光敏感;但并不表现为言语、运动增多。情绪症状:易烦恼、易激惹,也可表现在工作、学习效率下降或精力不足而焦急、苦恼,但无广泛的焦虑或原因不明的心境低沉。紧张性疼痛:如紧张性头痛、紧张性肌肉疼痛。睡眠障碍:如入睡困难、多梦、易醒、醒后不解乏等。
1.2 纳入标准:符合上述中医、西医诊断标准,年龄在17~65岁,病程在3个月以上者。
1.3 排除标准:年龄在17岁以下或65岁以上,妊娠或哺乳期妇女,过敏体质及对本药过敏者;足以引起本病症状的躯体疾病,脑器质性疾病、精神分裂症、歇斯底里、老年性痴呆等相当于中医的狂、癫等证者以及其它神经症如焦虑症、抑郁症、恐惧症、疑病症、强迫症等;合并有心血管、肝、肾和造血系统等严重原发性疾病者;不符合纳入标准,未按规定用药,无法判断疗效,或资料不全等影响疗效或安全性判断者。
1.4 实验设计
1.4.1 病例分配:采用随机单盲对照实验方法,治疗组不少于90例,对照组不少于30例。观察病人为门诊病人。
采取随机数字法,每个神经衰弱病人数字尾数为单数的人实验组,双数的入对照组。
1.4.2 对照药的选择:选择对神经衰弱有效的枣仁安神液,其主要成份为酸枣仁,作用为补心安神。适应症为失眠、头晕,健忘。
1.5 实验方法:实验组以本发明方基本方:夜交藤12g,钩藤13g,远志12g,茯神12g,柏子仁12g,酸枣仁12g,柴胡11g,川芎12g,延胡索12g,栀子12g,马鞭草12g,制首乌12g,女贞子13g,五味子12g,合欢皮12g,珍珠母12g,莪术12g,白芍12g,车前子12g,黄芩12g,菊花12g,生地12g,夏枯草12g。按本发明实施例2的方法制成口服液,每日3瓶。
对照组服用枣仁安神液(北京同仁堂股份有限公司同仁堂制药厂),每晚临睡前服,一次10ml,一日1次。疗程均为二周。
1.6 疗效性观测项目
1.6.1 神经衰弱临床症状:包括衰弱症状、兴奋症状、情绪症状、紧张性疼痛、睡眠障碍等,疗效分为:①无变化:原症状没有变化或加重;②改善1:有轻度改善;③改善2:有明显改善;④改善3:完全治愈该症状。以患者正常口述表达为主,医生观察为辅。
为简化研究,根据“1.1.1中医诊断标准”中的八个主要证候的出现次数和程度,计算两组治疗前和治疗后的中医证候积分,出现证候多、程度重则积分高。症状分级方法:0级(0分),无症状;1级(1分),症状轻微或偶尔出现,不影响工作和休息;2级(2分),症状时轻时重或间断出现;3级(3分),症状较重或持续出现,影响工作和休息。
1.7 疗效判定标准:痊愈:临床症状、体征消失或基本消失,证候积分减少≥95%;显效:临床症状、体征明显改善,证候积分减少≥70%;有效:临床症状、体征均有好转,证候积分减少≥30%;无效:临床症状、体征均无明显改善,证候积分减少不足30%。计算公式为:[(治疗前积分一治疗后积分)÷(治疗前积分)]×100%。
1.8 统计学方法:计数资料用检验,计量资料用t检验。检验水准为:α=0.05。
2 结果
2.1 一般资料:治疗组90例,男38例,女52例,年龄18~65岁,平均(37.5±5.2)岁;病程3个月~10年。
对照组32例,男14例,女18例,年龄22~65岁,平均(40.3±6.5)岁;病程3个月~12年。两组患者在年龄、性别分布,病程时间无差异(P>0.05),具有可比性。治疗前神经衰弱症状总积分和中医证候积分比较均无统计学意义(P>0.05),均衡性良好。
2.2 两组总体疗效比较:治疗组痊愈率为72.22%,显效率为14.44%,总有效率为95.56%;对照组痊愈率为37.5%,显效率为31.2%,总有效率为84.37%,两组比较痊愈率、显效率无差异(P>0.05),但总有效率差异有统计学意义(α=17.2,P<0.01)。
表1 治疗组和对照组疗效比较
**与对照组比较,P<0.01
2.3 对神经衰弱症状改善情况的比较治疗组对精神易兴奋、易激惹、头痛头昏、消化系统症状、性功能障碍的改善优于对照组(P<0.05)。
2.4 对神经衰弱痰湿内停证候积分的比较
表2 两组神经衰弱症状群改善情况比较
*与对照组比较,P<0.05;**与对照组比较,P<0.01
表3 治疗组和对照组治疗前后中医证候积分改善情况(x±s)
*与对照组比较,P<0.05;&P<0.01
治疗组与对照组治疗前积分差异无统计学意义;两组治疗后积分均下降,治疗后与治疗前积分比较差异统计学意义(P<0.05);治疗组治疗后积分低于对照组的治疗后积分。
3 讨论
心悸包括惊悸和怔忡,均为中医病名。是指病人自觉心中悸动,惊恐不安,甚则不能自主的一种症状。失眠是指经常不能获得正常4的睡眠而言。不寐的情况有多种,或不易入睡,或寐而易醒,醒后不能再度入睡,甚至彻夜不眠。总之,心悸和失眠往往并见,也常与头晕、头痛、耳鸣、健忘等症相互夹杂,每因情绪波动或劳累过度而发作。多见于西医学中的各种心心脏病,神经功能症、神经衰弱、植物神经功能紊乱等症。经常失眠会影响我们的正常工作和生活。经常失眠的朋友们由于白天没有精神往往导致白天精神不振,工作效率低,紧张易怒,与周围人相处不融洽,抑郁、烦闷、严重的还会导致悲观厌世。
肝开窍于目,目的视觉功能主要依赖肝之阴血的濡养;肝的经脉又上联目系。因此,肝的功能正常与否常常在目上反映出来。例如:肝血不足可出现视物模糊、夜盲;肝阴亏损,则两目干涩、视力减退;肝火上炎,则目赤肿痛。中医强调,人要经常疏肝气、清肝毒、降肝火、养肝血,疏肝气可使全身气机疏泄通畅,体内不堵则面上无痘;清肝毒可化解消除体内污染,体内无毒则脸无暗色;降肝火可使体内阴阳平衡,体内不焦则皮肤滋润不燥;养肝血可以滋养全身脏器,肝血充盈则体表光泽有弹性。修复受损肝脏,使全身气机疏泄条达,全身气血顺畅运行,以达到疏肝养颜目的。产生毒素的源头是肝。当肝不能很好地完成解毒工作时,毒素就在体内漫延。疏肝养颜首先从肝脏健康入手,让健康的肝脏完成各项解毒工作,彻底切断毒素来源,让容颜持久美丽。
循此思路,采用本发明减治疗神经衰弱,心悸失眠取得了较好的疗效。针对现代人脑力劳动者越来越多,城市生活压力巨大,许多人开始出现用脑过度、心悸失眠的症状,如记忆力下降、神经衰弱、思维迟钝等,心悸失眠。用脑过度会引起植物神经功能失调,从而引起脑血管舒缩功能异常,供血不足,出现头晕头痛胸闷、睡眠质量不高等症状。本发明清肝败火,滋阴补肾、生精补髓,益气养血,强脑安神。用于肝火上炎、气血两亏所致的头晕、乏力、健忘、心悸失眠;神经衰弱症见上述证候者,能较好的达到改善睡眠的功效。并且纯中药制剂,不会产生依赖性。对人身体无损害。神经衰弱的发病主因仍是精神心理因素,在中药治疗取得疗效后,仍宜注重心理保健,调整认知,改善不良的应对方式,才能避免复发。
根据血瘀论及肝主血,调血的理论,采用活血化瘀、疏肝调血(即调理脑血管壁舒缩功能)而达治疗目的。本发明具有补肾益精、化痰开窃、补脑益智、活血化癖作用。本发明清肝败火,滋阴补肾、生精补髓,益气养血,强脑安神。用于肝火上炎所致的头晕、乏力、健忘、心悸失眠;神经衰弱症见上述证候者,能较好的达到改善睡眠的功效。
Claims (10)
1.一种治疗肝火上炎型心悸失眠的中药制剂,其特征在于,所述中药制剂包括以下重量份数的原料:夜交藤10~20份,钩藤10~20份,远志10~20份,茯神10~20份,柏子仁10~20份,酸枣仁10~20份,柴胡10~20份,川芎10~20份,延胡索10~20份,栀子10~20份,马鞭草10~20份,制首乌10~20份,女贞子10~20份,五味子10~20份,合欢皮10~20份,珍珠母10~20份,莪术10~20份,白芍10~20份,车前子10~20份,黄芩10~20份,菊花10~20份,生地10~20份,夏枯草10~20份。
2.根据权利要求1所述治疗肝火上炎型心悸失眠的中药制剂,其特征在于,所述中药制剂中各种原料的重量份数为:夜交藤10~15份,钩藤10~15份,远志10~15份,茯神10~15份,柏子仁10~15份,酸枣仁10~15份,柴胡10~15份,川芎10~15份,延胡索10~15份,栀子10~15份,马鞭草10~15份,制首乌10~15份,女贞子10~20份,五味子10~20份,合欢皮10~20份,珍珠母10~20份,莪术10~20份,白芍10~20份,车前子10~20份,黄芩10~20份,菊花10~20份,生地10~20份,夏枯草10~20份。
3.根据权利要求1所述所述治疗肝火上炎型心悸失眠的中药制剂,其特征在于,所述中药制剂中各种原料的重量份数为:夜交藤10~20份,钩藤10~20份,远志10~20份,茯神10~20份,柏子仁10~20份,酸枣仁10~20份,柴胡10~20份,川芎10~20份,延胡索10~20份,栀子10~20份,马鞭草10~20份,制首乌10~20份,女贞子10~15份,五味子10~15份,合欢皮10~15份,珍珠母10~15份,莪术10~15份,白芍10~15份,车前子10~15份,黄芩10~15份,菊花10~15份,生地10~15份,夏枯草10~15份。
4.一种如权利要求1~3项任一项所述治疗肝火上炎型心悸失眠的中药制剂的制备方法,其特征在于,所述中药制剂为丸剂时的制备步骤为:
a、取所有原料放入乙醇浸泡,热提取2次,为组分1;
b、将上述提取的药渣加水提取2次,为组分2;
c、将组分1与组分2合并浓缩;干燥成粉末罐装胶囊。
5.根据权利要求4所述治疗肝火上炎型心悸失眠的中药制剂的制备方法,其特征在于,所述步骤a中,取所有原料药泡入乙醇中,浸泡2小时以上,分别加占原料药总质量的8倍量、6倍量的乙醇提取2次,提取时间为2小时、1小时;合并2次提取液,提取液通过管式离心,得离心液,离心液过D 101大孔树脂进行吸附,先用水洗除杂,然后用70%的乙醇进行洗脱,收集洗脱液,减压浓缩,成浸膏,为组分成1。
6.根据权利要求4所述治疗肝火上炎型心悸失眠的中药制剂的制备方法,其特征在于,所述步骤b中,将提取过的药渣加水,浸泡1-2小时;将浸泡好的药渣置多功能提取罐中煎煮二次;第一次加占其质量10倍量的水,煎煮1.5~2小时,取煎液,滤过;第二次加占其7倍量的水,煎煮1~1.2小时,取两次煎液混合,滤过;将上述两种提取液合并,浓缩成浸膏,作为组分2。
7.根据权利要求4所述治疗肝火上炎型心悸失眠的中药制剂的制备方法,其特征在于,所述步骤c中,将上述步骤得到的组分1与组分2混合,置入双效真空浓缩器中,浓缩成膏状,回收乙醇,然后通入喷雾干燥机进行喷雾干燥,过喷雾干燥机喷头的压缩空气压力为4kg/m 2,干燥室热气流温度是80℃,得原料药粉;罐装胶囊。
8.一种如权利要求1~3中任一项所述治疗肝火上炎型心悸失眠的中药制剂的制备方法,其特征在于,所述中药制剂为丸剂时的制备步骤为:
a.将所述原料放入粉碎机粉碎后过筛;
b.将过筛后剩下的颗粒物放入乙醇中加热回流提取2次;
c.再取上述乙醇提取后的药渣,加水加热回流提取1次;
d.将上述两种提取液合并,减压回收乙醇并喷雾干燥,得药粉;混合过筛得到的细粉加蜂蜜搓成丸剂。
9.根据权利要求8所述治疗肝火上炎型心悸失眠的中药制剂的制备方法,其特征在于,所述步骤a中,将所述原料放入粉碎机粉碎后过120目细筛,使能通过120目筛的细粉量在达到30%,收集通过120目筛的原料细粉备用;所述步骤b中,将过筛后剩下的颗粒物放入乙醇中加热回流提取2次,每次1~2小时,将2次提取液合并静置。
10.根据权利要求8所述治疗肝火上炎型心悸失眠的中药制剂的制备方法,其特征在于,所述步骤c中,将上述乙醇提取过的药渣加10倍量水加热1~2小时回流提取1次;将上述3次提取液合并静置;所述步骤d中,将上述提取液合并,减压浓缩相对密度为80℃时1.28的滤液,回收乙醇,将所得滤液调整比重到1.50,通入喷雾干燥机进行喷雾干燥,过喷雾干燥机喷头的压缩空气压力为4kg/m 2,干燥室热气流温度是80℃,得原料药粉;将过筛后得到的原料细粉与乙醇提炼药粉混合,加蜂蜜搓成丸剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510424373.6A CN104940844A (zh) | 2015-07-17 | 2015-07-17 | 一种治疗肝火上炎型心悸失眠的中药制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510424373.6A CN104940844A (zh) | 2015-07-17 | 2015-07-17 | 一种治疗肝火上炎型心悸失眠的中药制剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104940844A true CN104940844A (zh) | 2015-09-30 |
Family
ID=54156267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510424373.6A Pending CN104940844A (zh) | 2015-07-17 | 2015-07-17 | 一种治疗肝火上炎型心悸失眠的中药制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104940844A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106362098A (zh) * | 2016-11-11 | 2017-02-01 | 东莞市百替生物科技有限公司 | 一种治疗肝阳上逆证的中药制剂及制备方法 |
CN106389823A (zh) * | 2016-11-11 | 2017-02-15 | 东莞市百替生物科技有限公司 | 一种治疗心气虚的中药制剂及制备方法 |
CN107638452A (zh) * | 2017-09-16 | 2018-01-30 | 吉林医药学院 | 一种具有改善睡眠功效的中药组合物的制备方法 |
WO2018042384A1 (en) * | 2016-09-02 | 2018-03-08 | Pharmacogenetics Limited | Compositions of medicinal plants for reducing the effects of aging, prevention and treatment of age-related neurodegenerative diseases, and treatment of anxiety and sleep disorders |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103007234A (zh) * | 2012-12-28 | 2013-04-03 | 青岛华仁信息技术开发有限公司 | 一种治疗子宫内膜异位引起痛经的中药制剂及其制备方法 |
CN104398986A (zh) * | 2014-11-27 | 2015-03-11 | 青岛申达高新技术开发有限公司 | 一种安神补脑的淫羊藿口服液及其制备方法 |
-
2015
- 2015-07-17 CN CN201510424373.6A patent/CN104940844A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103007234A (zh) * | 2012-12-28 | 2013-04-03 | 青岛华仁信息技术开发有限公司 | 一种治疗子宫内膜异位引起痛经的中药制剂及其制备方法 |
CN104398986A (zh) * | 2014-11-27 | 2015-03-11 | 青岛申达高新技术开发有限公司 | 一种安神补脑的淫羊藿口服液及其制备方法 |
Non-Patent Citations (1)
Title |
---|
魏霞: "麻应富主任医师治疗失眠临床经验总结", 《河南中医》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018042384A1 (en) * | 2016-09-02 | 2018-03-08 | Pharmacogenetics Limited | Compositions of medicinal plants for reducing the effects of aging, prevention and treatment of age-related neurodegenerative diseases, and treatment of anxiety and sleep disorders |
US10722547B2 (en) | 2016-09-02 | 2020-07-28 | Pharmacogenetics Limited | Compositions of medicinal plants for reducing the effects of aging, prevention and treatment of age-related neurodegenerative diseases, and treatment of anxiety and sleep disorders |
CN106362098A (zh) * | 2016-11-11 | 2017-02-01 | 东莞市百替生物科技有限公司 | 一种治疗肝阳上逆证的中药制剂及制备方法 |
CN106389823A (zh) * | 2016-11-11 | 2017-02-15 | 东莞市百替生物科技有限公司 | 一种治疗心气虚的中药制剂及制备方法 |
CN107638452A (zh) * | 2017-09-16 | 2018-01-30 | 吉林医药学院 | 一种具有改善睡眠功效的中药组合物的制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102078520B (zh) | 一种治疗神经性头痛的中药制剂及其制备方法 | |
CN103007035B (zh) | 一种清肝明目的枸杞叶中药茶饮及其制备方法 | |
CN103520572B (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
CN104398986A (zh) | 一种安神补脑的淫羊藿口服液及其制备方法 | |
CN104491759A (zh) | 一种治疗偏头痛的中药组合物及其制备方法 | |
CN103041264B (zh) | 一种防治血管性痴呆葛根补脑益智口服液及其制备方法 | |
CN103041309A (zh) | 一种银杏叶美容口服液及其制备方法 | |
CN104398790A (zh) | 一种防治心悸失眠、神经衰弱的罗布麻叶口服液及其制备方法 | |
CN104208581A (zh) | 一种预防酒精肝的五味子保健口服液及其制备方法 | |
CN104940844A (zh) | 一种治疗肝火上炎型心悸失眠的中药制剂及其制备方法 | |
CN103719493A (zh) | 一种补脑益智的黄精保健茶及其制备方法 | |
CN105125946A (zh) | 一种清心除烦的栀子口服液及其制备方法 | |
CN105999113B (zh) | 一种治疗顽固性失眠的中药组合物及其制备方法 | |
CN102178781B (zh) | 一种治疗阴囊湿疹的中药组合物及其制备方法 | |
CN105497789A (zh) | 一种治疗脑卒中后抑郁症的中药制剂及其制备方法 | |
CN104888158A (zh) | 一种提高免疫力的罗布麻叶口服液及其制备方法 | |
CN102048913B (zh) | 一种治疗更年期综合症的中药制剂及其制备方法 | |
CN104888152A (zh) | 一种治疗产后抑郁的中药制剂及其制备方法 | |
CN104547598A (zh) | 一种治疗神经衰弱的中药制剂及制备方法 | |
CN104127663A (zh) | 一种治疗阴虚火旺型经行失眠的中成药 | |
CN103933538A (zh) | 用于治疗脾肾阳虚型肝硬化腹水的药物及其制备方法 | |
CN104524479B (zh) | 一种治疗经前期综合征的中药组合物及其制备方法 | |
CN105535587A (zh) | 一种治疗心肾不交型心悸失眠的中药制剂及其制备方法 | |
CN104398734A (zh) | 一种补血养颜的桑寄生口服液及其制备方法 | |
CN104689151A (zh) | 一种治疗糖尿病的中药组合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150930 |